Inhibikase Therapeutics Inc.
06/29/2022 | Press release | Distributed by Public on 06/29/2022 14:01
Submission of Matters to a Vote of Security Holders - Form 8-K
8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 24, 2022
INHIBIKASE THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware (State or Other Jurisdiction of Incorporation) |
001-39676 (Commission File Number) |
26-3407249 (IRS Employer Identification No.) |
|
3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia |
30339 |
|
|
(Address of Principal Executive Offices) |
(Zip Code) |
Registrant's Telephone Number, Including Area Code: (678) 392-3419
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
||
|
Common Stock, $0.001 par value |
IKT |
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.07 |
Submission of Matters to a Vote of Security Holders. |
The 2022 Annual Meeting of Stockholders ("Annual Meeting") of Inhibikase Therapeutics, Inc. (the "Company") was held on June 24, 2022. The following proposals were approved at the Annual Meeting by the votes indicated:
Proposal One: To elect two directors to the board of directors of the Company to serve as Class II directors, to serve until the Company's 2025 annual meeting of stockholders or until in each case their respective successor is duly elected and qualified. The nominees for election were Roy Freeman, M.D and Paul Grint, M.D.
The following nominees were elected by the votes indicated to serve as Class II directors, to serve until the Company's 2025 annual meeting of stockholders or until their respective successors are duly elected and qualified:
|
Name |
Total Votes |
Total Votes |
Total Broker |
|||||||||
|
Roy Freeman, M.D. |
11,443,604 |
574,448 |
4,467,473 |
|||||||||
|
Paul Grint, M.D. |
11,530,376 |
487,676 |
4,467,473 |
Proposal Three: To ratify the appointment of CohnReznick LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2022.
|
Total Votes |
||||
|
For |
16,397,389 |
|||
|
Against |
31,521 |
|||
|
Abstain |
56,614 |
|||
|
Broker Non-Votes |
0 |
-2-
The following proposal was not adopted at the Annual Meeting by the votes indicated because the requisite approval percentage was not met:
Proposal Two: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 200,000,000.
|
Total Votes |
||||
|
For |
15,007,293 |
|||
|
Against |
1,428,440 |
|||
|
Abstain |
49,792 |
|||
|
Broker Non-Votes |
0 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: June 29, 2022 |
INHIBIKASE THERAPEUTICS, INC. |
|||||
|
By: |
/S/ MILTON H. WERNER |
|||||
|
Milton H. Werner, Ph.D. |
||||||
|
President and Chief Executive Officer |
-3-